NASDAQ:MDCO - The Medicines Stock Price, News & Analysis

$32.71
+1.19 (+3.78 %)
(As of 08/18/2019 06:56 AM ET)
Today's Range
$31.63
Now: $32.71
$32.76
50-Day Range
$31.6150
MA: $35.77
$38.36
52-Week Range
$16.69
Now: $32.71
$41.33
Volume999,600 shs
Average Volume1.09 million shs
Market Capitalization$2.60 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.02
The Medicines Company, a biopharmaceutical company, focuses on developing therapeutics for the treatment of therosclerotic cardiovascular disease. The company is developing Inclisiran, an investigational RNA interference therapeutic that inhibits production of proprotein convertase subtilisin/kexin type 9, which controls LDL-cholesterol levels. It has collaboration agreement with Alnylam Pharmaceuticals, Inc The Medicines Company was founded in 1996 and is headquartered in Parsippany, New Jersey.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:MDCO
CUSIP58468810
Phone973-290-6000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.14 million
Book Value$0.48 per share

Profitability

Net Income$-123,160,000.00

Miscellaneous

Employees62
Market Cap$2.60 billion
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable

Receive MDCO News and Ratings via Email

Sign-up to receive the latest news and ratings for MDCO and its competitors with MarketBeat's FREE daily newsletter.


The Medicines (NASDAQ:MDCO) Frequently Asked Questions

What is The Medicines' stock symbol?

The Medicines trades on the NASDAQ under the ticker symbol "MDCO."

How were The Medicines' earnings last quarter?

The Medicines Company (NASDAQ:MDCO) announced its quarterly earnings data on Wednesday, July, 24th. The company reported ($0.71) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.73) by $0.02. During the same quarter in the previous year, the firm posted ($0.63) earnings per share. View The Medicines' Earnings History.

When is The Medicines' next earnings date?

The Medicines is scheduled to release their next quarterly earnings announcement on Thursday, November 14th 2019. View Earnings Estimates for The Medicines.

What price target have analysts set for MDCO?

10 equities research analysts have issued 1-year target prices for The Medicines' stock. Their predictions range from $43.00 to $110.00. On average, they anticipate The Medicines' stock price to reach $64.2222 in the next twelve months. This suggests a possible upside of 96.3% from the stock's current price. View Analyst Price Targets for The Medicines.

What is the consensus analysts' recommendation for The Medicines?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for The Medicines in the last year. There are currently 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for The Medicines.

Has The Medicines been receiving favorable news coverage?

Media stories about MDCO stock have trended negative on Sunday, according to InfoTrie Sentiment. The research group scores the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. The Medicines earned a news impact score of -2.3 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for The Medicines.

Are investors shorting The Medicines?

The Medicines saw a drop in short interest in the month of July. As of July 15th, there was short interest totalling 21,402,900 shares, a drop of 7.0% from the June 15th total of 23,010,400 shares. Based on an average trading volume of 1,510,000 shares, the days-to-cover ratio is currently 14.2 days. Approximately 30.4% of the company's shares are short sold. View The Medicines' Current Options Chain.

Who are some of The Medicines' key competitors?

What other stocks do shareholders of The Medicines own?

Based on aggregate information from My MarketBeat watchlists, some companies that other The Medicines investors own include Gilead Sciences (GILD), AbbVie (ABBV), Celgene (CELG), Micron Technology (MU), Alibaba Group (BABA), Intercept Pharmaceuticals (ICPT), Cisco Systems (CSCO), NVIDIA (NVDA), Johnson & Johnson (JNJ) and AT&T (T).

Who are The Medicines' key executives?

The Medicines' management team includes the folowing people:
  • Mr. Mark Timney, CEO & Director (Age 54)
  • Mr. Christopher J. Visioli, CFO & Treasurer (Age 43)
  • Mr. Stephen M. Rodin J.D., Exec. VP, Gen. Counsel & Sec. (Age 43)
  • Dr. Clive A. Meanwell, Chief Innovation Officer & Director (Age 61)
  • Dr. Goutham Krishna Gorti, VP & Head of Investor Relations

Who are The Medicines' major shareholders?

The Medicines' stock is owned by a number of of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (9.37%), Westfield Capital Management Co. LP (5.86%), Maverick Capital Ltd. (4.87%), Iridian Asset Management LLC CT (4.35%), Camber Capital Management LP (2.14%) and Artal Group S.A. (1.26%). Company insiders that own The Medicines stock include Alexander J Denner, Armin M Kessler, Christopher T Cox, Clive Meanwell, Fredric N Eshelman, Mark Timney, Melvin K Spigelman, Stephen M Rodin and William Crouse. View Institutional Ownership Trends for The Medicines.

Which institutional investors are selling The Medicines stock?

MDCO stock was sold by a variety of institutional investors in the last quarter, including Jane Street Group LLC, Aviva Holdings Ltd., Camber Capital Management LP, Westfield Capital Management Co. LP, Iridian Asset Management LLC CT, Pinnacle Associates Ltd., SG Americas Securities LLC and Alberta Investment Management Corp. Company insiders that have sold The Medicines company stock in the last year include Clive Meanwell and Stephen M Rodin. View Insider Buying and Selling for The Medicines.

Which institutional investors are buying The Medicines stock?

MDCO stock was purchased by a variety of institutional investors in the last quarter, including Vivo Capital LLC, Balyasny Asset Management LLC, Vanguard Group Inc., Nuveen Asset Management LLC, Renaissance Technologies LLC, Artal Group S.A., University of Notre Dame DU Lac and Orbimed Advisors LLC. Company insiders that have bought The Medicines stock in the last two years include Alexander J Denner, Christopher T Cox, Fredric N Eshelman and Mark Timney. View Insider Buying and Selling for The Medicines.

How do I buy shares of The Medicines?

Shares of MDCO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is The Medicines' stock price today?

One share of MDCO stock can currently be purchased for approximately $32.71.

How big of a company is The Medicines?

The Medicines has a market capitalization of $2.60 billion and generates $6.14 million in revenue each year. The company earns $-123,160,000.00 in net income (profit) each year or ($2.91) on an earnings per share basis. The Medicines employs 62 workers across the globe.View Additional Information About The Medicines.

What is The Medicines' official website?

The official website for The Medicines is http://www.themedicinescompany.com/.

How can I contact The Medicines?

The Medicines' mailing address is 8 SYLVAN WAY, PARSIPPANY NJ, 07054. The company can be reached via phone at 973-290-6000 or via email at [email protected]


MarketBeat Community Rating for The Medicines (NASDAQ MDCO)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  463 (Vote Outperform)
Underperform Votes:  338 (Vote Underperform)
Total Votes:  801
MarketBeat's community ratings are surveys of what our community members think about The Medicines and other stocks. Vote "Outperform" if you believe MDCO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDCO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel